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Abstract  
INTRODUCTION: Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to 
stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis 
(TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin 
test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI. 
AIM: The study aims to present the first results with IGRA test compared with TST in the screening of LTBI and 
the treatment results in the cases with LTBI in Macedonia. 
MATERIAL AND METHODS: In this study 73 cases diagnosed and treated with LTBI in 2016 were included. For 
diagnosis of LTBI, we used TST RT -23 5T.U. and commercial IGRA test such as QuantiFERON-TB Gold In-Tube 
(QFT-IT). 
RESULTS: Out of 73 cases with LTBI, 61.64% were men, and 38.36% were women. Among all age groups, the 
most frequent were cases between 5 and 14 years old (54.79%). Among the evaluated risk groups for LTBI, the 
most frequent were children household contacts with pulmonary TB cases (61-83.65%), followed by people living 
with HIV (9-12.33%) and only 3 cases with other medical reasons. Positive TST had 34 cases (46.57%) and 
positive IGRA test 25 cases (34.25%). Regarding the treatment regimes, we use two regimes: 50 cases (68.44%) 
received 6 months daily regime with Isoniazid, and 23 cases (31.51%) received 3 months daily regime with 
Isoniazid and Rifampicin. Treatment outcomes showed that the most patients completed treatment regimes: 55 
(75.34%) and only 10 (13.09%) interrupted the treatment. 
CONCLUSION: Despite the progress made in the last few years, several challenges remain to be addressed for 
better management of LTBI which will contribute to strength TB control in the country. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Tuberculosis is one of the most prevalent 
infections of human beings and a formidable public 
health challenge that shows little sign of abating [1]. 
Primary infection with M. tuberculosis leads to clinical 
disease in only ~ 10% of individuals. In the remaining 
cases, the ensuing immune response arrests the 
further growth of M. tuberculosis. However, the 
pathogen is completely eradicated in only ~ 10% 
people, while the immune response in the remaining ~ 
90% individuals only succeeds in the containment of 
infection as some bacilli escape killing by blunting the 
microbicide mechanisms of immune cells and remain 
in no replicating (dormant or latent) state in old 
lesions. The process is termed as latent tuberculosis 
infection (LTBI) and is defined as a state of persistent 
immune response to stimulation by Mycobacterium 
tuberculosis antigens without evidence of clinically 
manifested active TB [2]. 
Persons with LTBI do not have active 
tuberculosis and do not feel sick but may develop it in 
the near or remote future, a process called TB 
reactivation [3]. The lifetime risk of reactivation TB for 
a person with documented LTBI is estimated to be 5 -
10%, with the majority developing TB disease within 
the first five years after initial infection and lifetime 
risk, is ~ 50% in HIV coinfected individuals [4][5]. 
However, the risk of developing TB disease following 
infection depends on several factors, the most 
important one being the immunological status of the 
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host. Finding LTBI provides an opportunity to treat 
and prevent reactivation of the latent infection that 
leads to active disease, especially in people with 
compromised immune systems.  
Systematic diagnosis and treatment of LTBI is 
part of the new End TB strategy by World Health 
Organization (WHO) and achieving ≥ 90% LTBI 
treatment coverage among people living with HIV 
(PLHIV), and child contacts of TB cases are one of 
the global priority targets [6]. 
Available tests to demonstrate prior 
tuberculosis infection include the tuberculin skin test 
(TST) and interferon-gamma release assays (IGRAs) 
[7]. 
In the Republic of Macedonia, the systematic 
screening for LTBI and treating people who have risk 
factors for developing active TB is part of the National 
tuberculosis program (NTP). The Macedonian national 
guideline for LTBI updated in 2016, recommends 
three main groups with risk factors for management of 
LTBI: children as household contacts of pulmonary TB 
cases, PLHIV and patients initiating anti-TNF 
treatment or receiving immunosuppressive therapy.  
The study aims to present our first results with 
IGRA test compared with TST in the screening of 
LTBI and the treatment results in the cases with LTBI. 
 
 
Material and Methods 
 
A retrospective cohort study was undertaken, 
based on data systematically collected on all persons 
undergoing the TST-based and the IGRA-based LTBI 
screening programme and treatment programme 
during 2016. All data were obtained from the Central 
unit for registration of TB and LTBI in the Republic of 
Macedonia, at the Institute for Lung Diseases and TB. 
In this study 73 cases diagnosed and treated with 
LTBI were included. For diagnosis of LTBI, we used 
TST RT-23 5T.U. and induration ≥ 5 mm was 
considered as positive results. The other test was 
commercial IGRA such as QuantiFERON-TB Gold In-
Tube (QFT-IT), and it was performed by measuring 
interferon-ɣ (IFN-ɣ) with Enzyme-Linked 
Immunosorbent Assay (ELISA). In the most cases, 
diagnosis of LTBI was obtained with both tests: with 
the exception that TST and IGRA test was not 
performed in 11 (15.07%) and 36 (49.1%) cases 
respectively. According to our national guidelines for 
treatment of LTBI, there are two used therapeutic 
regimes: the daily regime of Isoniazid (H) for 6 months 
or daily regime of Isoniazid and Rifampicin (R) for 3 
months. All cases with LTBI were followed during the 
treatment period, and the treatment outcomes were 
presented. 
The differences of category variables were 
present with the distribution of the frequencies. For 
comparison of the differences of the data Fischer-
exact test was used. A statistical difference was 
considered to be significant when the p-value was < 
0.05. 
 
 
Results 
 
Of 73 cases with LTBI, 61.64% were men, 
and 38.36% were women. According to the age, 61 
(83.56%) were children, and 12 (16.43) were adults. 
Among all age groups, the most frequent were cases 
between 5and 14 years old (54.79%), Table 1. 
Table 1: Distribution of cases with LTBI according to the 
gender and age groups 
Gender n (%) 
Men 45 ( 61.64) 
Women 28 ( 38.36) 
Total 73 (100.00) 
Age groups n (%) 
  0 – 4 21 (28.77) 
  5 – 14 40 (54.79) 
15 – 24 2 (2.74) 
25 – 34 4 (5.48) 
35 – 44 
45 – 54 
0 (0,%) 
5 (6.85) 
55 – 64 1 (1.37) 
Total 73 (100.00) 
 
In this study three groups of cases with risk 
factors were screened for LTBI and the most frequent 
were children household contacts with pulmonary TB 
cases (61-83.65%), followed by PLHIV (9-12.33%) 
and only 3 cases with other medical reasons: 1 case 
that initiated anti TNF therapy and 2 that received 
immunosuppressive therapy, named as others (Table 
2). According to the data from our NTP, in 2016 
among 360 TB contacts examined, 15 were TB cases 
(4.16%), and 61 were with LTBI (16.9%). 
Table 2: Different groups with risk factors for the screening of 
LTBI 
Risk groups n (%) 
Contact with TB cases 61 (83.56) 
PLHIV 9 (12.33) 
Others 3 (4.11) 
Total 73 (100.00) 
 
In Table 3 and Table 4 the results obtain with 
TST, and IGRA test was separately presented. In 
Table 5 the combination of both tests was presented, 
and it is obvious that in all cases included in the study 
one or both tests were performed.  
Table 3: Results of TST at the time of screening for LTBI 
TST test n (%) 
Negative 28 (38.36) 
Positive :5 – 14mm 11 (15.07) 
Positive :15 – 20mm 18 (24.66) 
Positive : 20 – 34mm 5 (6.85) 
Not done 11 (15.07) 
Total 73 (100.00) 
 
 Ilievska-Poposka et al. Latent Tuberculosis Infection - Diagnosis and Treatment 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
Even we used to perform both tests in each 
case; there were 11 cases without TST and 36 without 
IGRA test. TST confirmed 34 positive cases (46.57%), 
IGRA test 25 positive cases (34.25%) and both tests 
were positive in 11 cases (15.06%) and both negative 
in 6 cases (8.21%). 
Table 4: Results of IGRA test at the time of screening of LTBI 
IGRA test n (%) 
Negative 12 (16.44) 
Positive 25 (34.25) 
Not done 36 (49.31) 
Total 73 (100.00) 
 
There were 17 cases in which only TST was 
performed and 1case in which only IGRA was 
performed, and the results were negative. Those 18 
and those 6 cases were both tests confirmed to be 
negative, were without laboratory confirmation for 
LTBI (Total 24). 
Table 5: Combination of TST and IGRA  
Test IGRA pos IGRA neg IGRA not done Total 
TST pos 10 5 19 34 
TST neg 5 6 17 28 
TST not done 10 1 / 11 
Total 25 12 36 73 
 
In Macedonia, there is obligatory Bacillus 
Calmette–Guerin (BCG) vaccine for all newborn. 
Besides this, the results showed that nearly one-third 
of evaluated cases were with the negative status of 
BCG vaccination (Table 6). 
Table 6: BCG status of cases with LTBI 
BCG status n (%) 
Positive 51 (69.86) 
Negative 21 (28.77) 
Unknown 1 (1.37) 
Total 73 (100.00) 
 
Regarding different treatment regime for LTBI, 
50 cases received daily regime with H for 6 months 
and 23 cases received daily regime of H/R for 3 
months (Table 7). 
Table 7: Different treatment regime for LTBI 
Treatment regimes n (%) 
6 months Isoniazid 50 (68.49) 
3 months Isoniazid and Rifampicin 23 (31.51) 
Total 73 (100.00) 
 
Treatment outcomes showed that 75.34% of 
treated cases with LTBI completed treatment, and 
only 13.69% did not finish the whole regime (table 8). 
Table 8: Treatment outcomes in 73 cases with LTBI  
Treatment outcomes n (%) 
Completed treatment 55 (75.34) 
Interrupted treatment 10 (13.69) 
Interrupted treatment due to negative control TST 8 (10.96) 
Total 73 (100.00) 
 
In an aim to evaluate if there were some 
factors that influenced the treatment outcome, the 
correlation test was performed between the gender, 
age groups, different risk groups for detecting LTBI, 
different therapeutic regimes and the treatment 
outcomes, and we did not find any statistically 
significant correlation (Table 9).  
Table 9: Correlation of gender, age groups, risk groups and 
treatment regimes of cases with LTBI and treatment outcomes 
 Treatment outcome 
N Interrupted Completed Interrupted due to 
negative control 
TST 
Gender 
Men 45 (61.64) 7 (70) 33 (60) 5 (62.5) 
Women 28 (38.36) 3 (30) 22 (40) 3 (37.5) 
Fisher exact, two-tailed p = 0.9 
Age groups 
 0 – 4 21 (28.77) 2 (20) 16 (29.09) 3 (37.5) 
 5 – 14 40 (54.79) 6 (60) 29 (52.73) 5 (62.5) 
15 – 24 2 (2.74) 1 (10) 1 (1.82) 0 
25 – 34  4 (5.48) 0 4 (7.27) 0 
45 – 54  5 (6.85) 1 (10) 4 (7.27) 0 
55 – 64  1 (1.37) 0 1 (1.82) 0 
Fisher exact, two-tailed p = 0.875 
Risk groups 
Contact with TB 61 (83.56) 8 (80) 45 (81.81) 8 (100.0) 
PLHIV 9 (12.33 2 (20) 7 (12.73) 0 
Others 3 (4.11) 0  3 (5.45) 0 
Fisher exact, two-tailed p = 0.54 
Treatment regime 
6 months H 50 (68.49) 7 (70) 38 (69.09) 5 (62.5) 
3 months 
H/R 
23 (31.51) 3 (30) 17 (30.91) 3 (37.5) 
Fisher exact, two-tailed p = 0.54 
 
 
 
Discussion 
 
The presented study shows our results of 
using two tests (TST and IGRA) for detecting the LTBI 
in the Republic of Macedonia and treatment 
outcomes: in 2016 there were 73 cases diagnosed 
with LTBI that received preventive therapy. In 
Macedonia, for many years ago, only TST was used 
for screening the LTBI mostly among children 
household contacts of pulmonary TB cases; we did 
not use this test for screening LTBI among the adults 
even they were contacts with TB cases. All these 
adult contacts according to our NTP were screened 
only for active TB. Because BCG vaccination is 
obligatory for all newborns in Macedonia, it was 
difficult to interpret TST positive results: whether they 
are due to the cross-reaction with BCG vaccination, or 
to the infection with Mycobacterium tuberculosis. In 
2013, IGRA test with high specificity was introduced 
for screening LTBI in our NTP which meant to reduce 
false positivity due to BCG vaccination or 
nontuberculous mycobacteria (NTM) infection. In the 
beginning its indication was limited only to children 
contacts with TB cases and PLHIV, and after this first 
period we expanded the indication according to the 
recommendation from Guidelines on the management 
of latent tuberculosis infection [5] to the patients 
initiating anti-tumor necrosis factor (TNF) treatment, 
patients receiving dialysis, patients preparing for 
organ or hematologic transplantation, and patients 
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with silicosis, but its implementation was going very 
slowly. There is a modification in the Macedonian 
Guidelines for LTBI in 2016, from the 2008 
Guidelines. In 2016 there were only 9 cases with 
PLHIV and 3 cases with other medical risk factors 
screened and treated of LTBI. 
All cases with LTBI in this study were not 
screened with both tests: according to our practice for 
many years ago, TST was performed in all children -
61 and only in1 adults (62-84.93%). IGRA was 
performed in half of the cases (37-50.68%): 12 adults 
and 25 children. 
According to the data from the literature, there 
is no ideal test for detecting Mycobacterium 
tuberculosis infection even both tests are moderately 
sensitive and highly specific [7]. The disadvantages of 
TST include the need for two visits (to place the TST 
and to read it 48-72 hours later), inter-reader 
variability in measuring millimetres of induration, 
diminished response caused by immunosuppression, 
boosting on repeat testing, and potential cross-
reaction with nontuberculous mycobacteria and M. 
bovis BCG vaccine [8]. The introduction of the IGRA 
was an advance in diagnostic technology. IGRA 
detect LTBI by measuring IFN-gamma release in 
response to antigens present in Mycobacterium 
tuberculosis, but not BCG vaccine and most 
nontuberculous mycobacteria.  
The evidence base for these tests has 
expanded rapidly and now, the result of some 
systematic reviews indicate that in comparison to 
TST, IGRAs can detect LTBI with a higher specificity, 
negative (NPV) and positive (PPV) predictive values, 
as they are not confounded by previous BCG 
vaccination [9] [10] [11].  
Regarding the treatment regimes we use two 
regimes: 50 cases (68.44%) received 6months daily 
regime with H, and 23 cases (31.51%) received 
3months daily regime with HR. We have to comment 
that according to our results there were 24 cases 
without laboratory confirmation of LTBI, but besides 
that, they were treated with preventive therapy for 
LTBI. This was because they were children at 5 or 
under the age of 5 with very close household contact 
with pulmonary TB. It is according recommendations 
by WHO and other association that people living with 
HIV and children under the age of 5 years who are 
close household or close contact with people with TB 
and who have negative TST or IGRA results (with 
normal chest radiograph) should be treated for LTBI 
and another TST or IGRA performed 8-10 weeks after 
contact has ended. If a repeat TST or IGRA result is 
positive, treatment should be continued. If it is 
negative, treatment can usually be discontinued [5] 
[12] [13]. 
According to the Guidelines from WHO and 
the Centers for Disease Control and Prevention 
(CDC) there are four treatment regimes for LTBI: 9 or 
6 months of daily self-administered H, 4 months of 
daily self-administered R, 3 months of daily self -
administered H/R, and the newest 3 months of once-
weekly directly observed isoniazid-rifapentine [5][14]. 
WHO recommends either 6 or 9 months of daily 9H as 
the standard for treatment of LTBI [5]. For people 
living with HIV infection, 9 months of therapy is 
recommended. The benefits of preventive therapy to 
individuals with LTBI have been demonstrated in 
some randomised clinical trials [15] [16].  
The results from this study showed that most 
patients completed treatment regimes: 55 (75.34%) 
and only 10 (13.09%) interrupted the treatment. 8 
(10.96%) of them interrupted treatment because of 
negative control TST after 8 weeks of the window 
period. We did not find that some factors such as 
gender, age groups, different risk groups or treatment 
regimes correlated with the treatment outcomes. In 
our study cases, we did not register some serious 
adverse effects from therapy. In the study of Denholm 
et al. even adverse effects were frequently identified 
among the cases with LTBI, there were also, high 
levels of treatment adherence and completion [17]. 
The analysis from some studies identified the 
following determinants as detrimental to treatment 
completion: adverse drug reactions, longer duration of 
treatment, immigrant status, long distance from a 
health facility, the presence of stigma, alcohol and 
drug use, unemployment and time lag between 
diagnosis and treatment [5]. One randomised trial 
showed a significant increase in completion rate in the 
3-month weekly rifapentine plus isoniazid regimen 
compared to the 9-month isoniazid regimen [18].  
Analysis of this study presented the program 
for diagnosis and treatment of LTBI in Macedonia and 
compared the findings with the actual 
recommendations. When the IGRA's has been 
introduced in our program, big progress was made in 
the widening the indication for detecting LTBI. 
Detecting and treating cases who are at risk to 
develop active TB, will contribute to better control of 
TB in Macedonia. Using IGRA tests among household 
contacts with pulmonary TB will help for better 
selection of cases that need preventive therapy. 
Despite the progress, several challenges remain to be 
addressed: further strengthening in the optimum use 
of both tests, to assess the ability of these tests to 
predict tuberculosis disease, their reproducibility over 
serial tests, and discordance between tests. 
Regarding the treatment as soon as possible we 
should provide the use of 3 months of once-weekly 
directly observed isoniazid-rifapentine regime. 
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